Status:
UNKNOWN
4Hz Transcranial Alternating Current Stimulation for Patients With Mild Alzheimer's Disease
Lead Sponsor:
Xuanwu Hospital, Beijing
Conditions:
Alzheimer Disease
Eligibility:
All Genders
45-75 years
Phase:
NA
Brief Summary
The goal of this study is to explore the efficacy and safety of 4Hz transcranial alternating current stimulation (tACS) in patients with mild Alzheimer's disease (AD). The study will recruit 40 indivi...
Detailed Description
Background: Recently, transcranial alternating current stimulation (tACS), which could interact with ongoing neuronal activity, has emerged as a potentially effective and promising treatment for Alzhe...
Eligibility Criteria
Inclusion
- Subjects with informed consent;
- 45-75 years of age;
- At least 6 years of education;
- AD according to the National Institute on Aging and the Alzheimer's Association (NIA-AA) guidelines;
- Clinical Dementia Rating Scale (CDR)=1.0;
- Positive findings in amyloid PET imaging or amyloid protein levels in CSF;
- On a stable dose of cholinesterase inhibitors (e.g. donepezil or rivastigmine) as defined as 6 consecutive weeks of treatment at an unchanging dose, and without any intentions to modify the dosage during the observation period.
Exclusion
- Current or past history of any neurological disorder other than dementia, such as epilepsy, stroke, progressive neurologic disease (e.g. multiple sclerosis), poorly controlled migraines or intracranial brain lesions; and history of previous neurosurgery or head trauma that resulted in residual neurologic impairment;
- Contraindication for undergoing MRI or receiving tACS;
- Eczema or sensitive skin;
- Familial AD;
- Depression or other psychiatric disorders;
- Abnormal brain structural magnetic resonance imaging (MRI) scan, including hydrocephalus, stroke, structural lesions, etc. that would potentially confound the outcome;
- Severe cardiovascular/pulmonary disorders;
- Other conditions, in the investigator's opinion, might not be suitable for the study.
Key Trial Info
Start Date :
October 14 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2023
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04088643
Start Date
October 14 2019
End Date
December 1 2023
Last Update
July 13 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Xuanwu Hospital, Capital Medical University
Beijing, China, 100053